Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076375 · ClinicalTrials.gov registry record · Phase 2
Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema)
A Phase 2 study of Atopic Dermatitis and Eczema, sponsored by Nucryst Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 19
- Study locations
NCT00076375: Completed Phase 2 study of Atopic Dermatitis and Eczema, sponsored by Nucryst Pharmaceuticals.
NCT00076375 is a Phase 2 study of Atopic Dermatitis and Eczema that has completed, run by Nucryst Pharmaceuticals. The registered enrollment target is 180 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (70% lower). The trial reports 19 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00076375, a Phase 2 study of Atopic Dermatitis and Eczema, has completed, sponsored by Nucryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 19
- Study locations
Study Summary
Nanocrystalline silver (very small particles of silver) is the active ingredient in Acticoat dressings, which have been approved for the treatment of burns and other wounds. Silver has been used for decades as an effective antimicrobial agent. In animal studies, nanocrystalline silver cream (NPI) has also demonstrated anti-inflammatory activity. Thus, nanocrystalline silver cream is being evaluated in the treatment of inflammatory skin conditions such as atopic dermatitis (eczema). Approximately 180 study subjects with a definitive diagnosis of mild to moderate eczema will be enrolled in this study. Subjects will be randomly assigned to treatment with placebo, 0.5% NPI or 1% NPI for the 6-week treatment period. Assessments of treatment effect and safety will be performed weekly. Upon completion of the study, subjects may be eligible for 12 weeks of open-label treatment with 1% NPI.
Conditions Studied
Interventions
- DRUG Nanocrystalline silver cream (NPI)
Study Locations (19)
Alabama
- Radiant Research - Birmingham
- Medical Affliated Research Centers, Inc. - Huntsville
New York
- Sadick Dermatology & Aesthetic Surgery - New York
- Mount Sinai School of Medicine - New York
Ohio
- University Hospitals of Cleveland - Cleveland
- Radiant Research - Columbus
South Carolina
- National Allergy, Asthma & Urticaria Centers of Charleston, P.A. - Charleston
- Radiant Research - Greer
Colorado
- National Jewish Medical & Research Center - Denver
District of Columbia
- nTouch Research - Washington D.C.
Florida
- Radiant Research - West Palm Beach
Idaho
- Radiant Research - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2003-11 |
| Est. Completion | 2004-04 |
| Phase | Phase 2 |
What the finished NCT00076375 record still lists
NCT00076375 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Nanocrystalline silver cream (NPI) is the first listed.
NCT00076375 lists 19 locations in 15 states (Alabama, New York, Ohio).
Frequently Asked Questions
What is clinical trial NCT00076375 about?
NCT00076375 is a clinical study titled "Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema)". Nanocrystalline silver (very small particles of silver) is the active ingredient in Acticoat dressings, which have been approved for the treatment of burns and other wounds. Silver has been used for decades as an effective antimicrobial agent. In animal studies, nanocrystalline silver cream (NPI) ha...
What is the current status of trial NCT00076375?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2003-11. Estimated completion is 2004-04.
What conditions does trial NCT00076375 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Eczema.
What interventions are being tested in trial NCT00076375?
The interventions under investigation include: Nanocrystalline silver cream (NPI) (DRUG).
Who is sponsoring clinical trial NCT00076375?
This trial is sponsored by Nucryst Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00076375 being conducted?
This trial has 19 study locations across Alabama, Colorado, District of Columbia, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00076375's enrollment target sits among peer trials
180 65th of 150 higher than 85 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia